Leqembi Program Learning Hub

This private workspace is designed to help me organize and deepen my understanding of Leqembi, anti-amyloid treatment programs, patient eligibility, monitoring requirements, and relevant research. It is currently intended as an internal learning and planning resource, with the possibility of later evolving into a more polished educational page.

A working space for organizing treatment criteria, program workflows, research findings, and clinical questions related to early Alzheimer’s disease treatment.

START HERE

Short intro, quick links, current priorities

1. Overview / Dashboard

This should be your landing page. Think of it as your command center.

Sections:

What this hub is
A short paragraph explaining that this is your private learning and program-development workspace.

At-a-glance
A simple section with boxes such as:

  • What is Leqembi?

  • Who is eligible?

  • What are the main risks?

  • What does the program workflow look like?

  • What do I still need to clarify?

Quick links
Buttons to your subpages:

  • Eligibility

  • Safety

  • Program workflow

  • Research summaries

  • My notes

Current priorities
A short list like:

  • Learn inclusion/exclusion criteria

  • Clarify MRI schedule

  • Understand neuropsych role in screening and follow-up

  • Clarify hospital workflow and documentation requirements

This page should feel very clean and not text-heavy.

I think you’d benefit from a recurring section called:

What seems clear / What still feels murky

For any complicated area, split it into:

  • What seems established

  • What varies by program

  • What I need to ask locally

That would be especially useful here, because some things are fixed by labeling/guidance, while other things are program-specific.

Section 1: Treatment Overview

  • Leqembi (lecanemab) is a medication used to treat early Alzheimer’s disease, including people with mild cognitive impairment (MCI) due to Alzheimer’s disease or mild Alzheimer’s dementia.

    It is part of a newer group of treatments called anti-amyloid therapies, which are designed to target one of the biological changes that occurs in Alzheimer’s disease.

    Leqembi works by helping the body remove amyloid-beta, a protein that can accumulate in the brain and form plaques. These plaques are believed to play a role in the development and progression of Alzheimer’s disease.

    Leqembi is considered a disease-modifying therapy, meaning it aims to slow the underlying disease process.

    Some important points to understand:

    • Leqembi does not cure Alzheimer’s disease
    • It is intended for people in the early stages of the disease
    • It works by slowing progression, not reversing existing symptoms
    • It requires regular infusions and medical monitoring

    Because the treatment targets a specific biological process in Alzheimer’s disease, special testing is required before treatment to confirm that amyloid is present in the brain.

  • Leqembi is a type of medication called a monoclonal antibody. Monoclonal antibodies are laboratory-designed proteins that recognize and attach to very specific targets in the body.

    In Alzheimer’s disease, one of the key biological changes is the buildup of amyloid-beta proteins in the brain. These proteins can cluster together and form amyloid plaques, which are thought to contribute to nerve cell damage and cognitive decline.

    Leqembi works by:

    1. Binding to soluble amyloid-beta aggregates (especially protofibrils)

    2. Marking these proteins for removal

    3. Allowing the body’s immune system to clear them from the brain

    Over time, this process can reduce the amount of amyloid in the brain, which may help slow the progression of the disease.

    In clinical trials, treatment with Leqembi was associated with:

    • Reduction of amyloid plaque levels in the brain
    • Slower cognitive and functional decline compared to placebo

    However, because the medication activates immune processes in the brain, careful monitoring with MRI scans is required to watch for possible side effects such as ARIA (amyloid-related imaging abnormalities).

  • Description text goes here

  • Item description

Section 2: Eligibility Criteria

  • Description text goes here

  • Description text goes here

  • Description text goes here

  • Item description

Section 3: Monitoring and Safety

  • Description text goes here

  • Description text goes here

  • Description text goes here

  • Item description

Section 4: Infusion Program Structure

  • Description text goes here

  • Description text goes here

  • Description text goes here

  • Item description

Section 5: Research Library

Table of key studies

Section 6: Questions & Notes

Working questions for further exploration.